41995-19-1

Usage

Uses

Used in Pharmaceutical Research and Development:
2-(3,4-Dichlorophenyl)-2-oxoethylamine hydrochloride is used as a key intermediate in the synthesis of new drugs and medications for various therapeutic areas. Its chemical structure and properties make it a versatile building block in the development of innovative pharmaceutical compounds.
Used in Drug Synthesis:
In the pharmaceutical industry, 2-(3,4-Dichlorophenyl)-2-oxoethylamine hydrochloride is used as a precursor in the synthesis of active pharmaceutical ingredients. Its reactivity and functional groups enable the formation of diverse chemical entities with potential therapeutic effects.
Used in Medicinal Chemistry:
2-(3,4-Dichlorophenyl)-2-oxoethylamine hydrochloride is employed as a starting material in medicinal chemistry for the design and optimization of drug candidates. Its structural features allow for the exploration of novel chemical space and the identification of promising lead compounds.
Used in Neurological and Psychiatric Drug Development:
Given its potential applications in the treatment of various diseases and disorders, 2-(3,4-Dichlorophenyl)-2-oxoethylamine hydrochloride is used as a research tool in the development of drugs targeting neurological and psychiatric conditions. Its chemical properties may contribute to the modulation of neurotransmitter systems or the enhancement of neuronal function, offering new therapeutic options for patients.
Used in Drug Formulation:
As a hydrochloride salt, 2-(3,4-Dichlorophenyl)-2-oxoethylamine hydrochloride is used in drug formulation to improve the solubility and bioavailability of the final pharmaceutical product. Its water-soluble nature facilitates the development of formulations suitable for various routes of administration, such as oral, injectable, or topical.

InChI:InChI=1/C8H7Cl2NO.ClH/c9-6-2-1-5(3-7(6)10)8(12)4-11;/h1-3H,4,11H2;1H

Upstream product

• 380650-10-2 2-amino-1-(3,4-dichloro-phenyl)-ethanone 
• 2632-10-2 2-bromo-1-(3,4-dichlorophenyl)ethanone 
• 2642-63-9 3',4'-dichloroacetophenone 
• 875306-52-8 C₁₀H₇Cl₂NO₃ 
• 318949-24-5 (3,4-dichloro-phenacyl)-hexamethylenetetraminium; bromide 

Downstream Products

• 64748-91-0 N-[2-(3,4-dichloro-phenyl)-2-oxo-ethyl]-2-(2,4-dioxo-imidazolidin-1-ylimino)-acetamide 
• 663181-08-6 C₁₄H₁₀Cl₂N₂O₂ 
• 3567-82-6 2-amino-1-(3,4-dichlorophenyl)ethan-1-ol 
• 1254941-84-8 2-(3-([1,2,4]triazolo[1,5-a;]pyridin-6-yl)benzylamino)-1-(3,4-dichlorophenyl)ethanol 
• 1190234-79-7 ethyl 1-(2-{[2-(3,4-dichlorophenyl)-2-oxoethyl]amino}-2-oxoethyl)-3-(trifluoromethyl)-1H-pyrazole-4-carboxylate 

Relevant academic research and scientific papers

NOVEL ARYL-CYANOGUANIDINE COMPOUNDS

The present invention relates to protein-lysine N-methyltransferase SMYD2 (SET and MYND domain-containing protein 2) inhibitors, in particular SMYD2-inhibitory substituted cyanoguanidine-pyrazolines of general formula (I) wherein R1, R2/s

NOVEL ARYL-CYANOGUANIDINE COMPOUNDS

The present invention relates to protein-lysine N-methyltransferase SMYD2 (SET and MYND domain-containing protein 2) inhibitors, in particular SMYD2-inhibitory substituted cyanoguanidine-pyrazolines of general formula (I), wherein R1, R3, R4, R5 and n have the meaning as described and defined herein, as well as to pharmaceutical compositions comprising compounds according to the invention and to their prophylactic and therapeutic use for hyperproliferative disorders, in particular for cancer, respectively tumour disorders. The present invention furthermore relates to the use of SMYD2 inhibitors for benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, neurodegenerative disorders, inflammatory disorders, atherosclerotic disorders and the control of male fertility.

NOVEL ARYL-CYANOGUANIDINE COMPOUNDS

The present invention relates to protein-lysine N-methyltransferase SMYD2 (SET and MYND domain-containing protein 2) inhibitors, in particular SMYD2-inhibitory substituted cyanoguanidine- pyrazolines of general formula (I), wherein R1, R2, R3, R4 and R5 have the meaning as described and defined herein, as well as to pharmaceutical compositions comprising compounds according to the invention and to their prophylactic and therapeutic use for hyperproliferative disorders, in particular for cancer, respectively tumour disorders. The present invention furthermore relates to the use of SMYD2 inhibitors for benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, neurodegenerative disorders, inflammatory disorders, atherosclerotic disorders and the control of male fertility.

CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF

Novel [1,2,4]triazolo[1,5-a]pyridinyl-6-yl-substituted tetrahydroisoquinolines are described in the present invention. These compounds and crystalline forms SA1 and N-2 are used in the treatment of various neurological and physiological disorders. Methods of making these compounds and crystalline forms SA-1 and N-2 are also described in the present invention.

ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF

Novel aryl, heteroaryl, and non-aromatic heterocyle substituted tetrahydroisoquinolines are described in the present invention. These compounds are used in the treatment of various neurological and physiological disorders. Methods of making these compounds are also described in the present invention.

7-([1,2,4,]TRIAZOLO[1,5,-A]PYRIDIN-6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4- TETRAHYDROISOQUINOLINE AND USE THEREOF

Novel [l,2,4]triazolo[l,5-α]pyridinyl-6-yl-substituted tetrahydroisoquinolines are described in the present invention. These compounds and crystalline forms SAl and N-2 are used in the treatment of various neurological and physiological disorders. Methods of making these compounds and crystalline forms SA-I and N-2 are also described in the present invention.

Indole, indazole and indoline derivatives as CETP inhibitors

The present invention relates to compounds of formula (I): wherein —X—Y—, R1 to R11 and n are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are mediated by CETP inhibitors.

Prenylation inhibitors and methods of their synthesis and use

The present invention is directed to compounds useful in the treatment of diseases associated with prenylation of proteins and pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising same, and to methods for inhibiting protein prenylation in an organism using the same.

1-[[[5-(Substituted phenyl)-2-oxazolyl]methylene]amino]-2,4-imidazolidinediones

A series of 1-[[[5-(substituted phenyl-2-oxazolyl]methylene]amino]-2,4-imidazolidinediones are useful as muscle relaxants.